Genscript Biotech First Half 2024 Earnings: Revenues Beat Expectations, EPS Lags

Genscript Biotech (HKG:1548) First Half 2024 Results

Key Financial Results

• Revenue: US$561.4m (up 44% from 1H 2023).
• Net loss: US$175.1m (loss widened by 87% from 1H 2023).
• US$0.083 loss per share (further deteriorated from US$0.044 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Genscript Biotech Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia.

Performance of the market in Hong Kong.

The company's shares are up 2.2% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Genscript Biotech that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.